544
Participants
Start Date
January 19, 2018
Primary Completion Date
August 23, 2021
Study Completion Date
October 31, 2021
P2B001 0.6/0.75 mg
Fixed low dose extended release combination capsule of pramipexole and rasagiline
Rasagiline 0.75 mg
Rasagiline 0.75 mg oral extended release capsule, component
Pramipexole 0.6 mg
Pramipexole 0.6 mg oral extended release capsule, component
Marketed Pramipexole ER
Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
P2B001/003 New York, New York
P2B001/003 Study site Brooklyn, Brooklyn
P2B001/003 Site Commack, Commack
P2B001/003 Study site Berlin, Berlin
P2B001/003 Study site Berlin, Berlin
P2B001 Study site Syracuse, Syracuse
P2B001/003 Study site Williamsville, Williamsville
P2B001/003 Study site Hershey, Hershey
P2B001/003, Falls Church
P2B001/003 Study site Alexandria, Alexandria
P2B001/003 Study site Navarra Madrid, Madrid
P2B001/003 study site Madrid, Madrid
P2B001/003 Study site Madrid, Madrid
P2B001/003 Study site La Paz, Madrid
P2B001/003 Study site Puerta de Hierro - Majadahonda, Majadahonda
P2B001/003 Site Asheville, Asheville
P2B001/003 study site Mostoles, Móstoles
P2B0011/003 Study site HM Centro Integral de Neurociencias (CINAC), Madrid
P2B001/003 Greenville, Greenville
P2B001/003 Site Augusta, Augusta
P2B001/003 Study site Pamplona, Pamplona
P2B001/003 study site Jacksonville, Jacksonville
P2B001/003 site Miami, Miami
P2B001/003 site Boca Raton, Boca Raton
P2B001/003 Site Boca Raton, Boca Raton
P2B001/003 Site Tampa, Tampa
P2B001/003 Site Port Charlotte, Port Charlotte
P2B001/003 Site Sarasota, Sarasota
P2B001/003 Study site Nashville, Nashville
P2B0011/003 Study Veracity Neuroscience, Memphis
p2B001/003 Study site Memphis, Memphis
P2B001/003 Site Lexington, Lexington
P2B001/003 Site Toledo, Toledo
P2B001/003 Study site Bochum, Bochum
P2B001 study site Cincinnati, Cincinnati
P2B001/003 Study site Münster, Münster
P2B001/003 study site west Bloomfield, West Bloomfield
P2B001/003 Site East Lansing, East Lansing
P2B001/003 Site Golden Valley, Golden Valley
P2B001/003 Site Winfield, Winfield
P2B001/003 site Chicago, Chicago
P2B001/003 site St. Louis, St Louis
P2B001/003 Study site Hanau, Hanau
P2B001/003 site Kansas City, Kansas City
P2B001/003 Study site little Rock, Little Rock
P2B001/003 Site Dallas, Dallas
P2B001/003 Study site Freiburg, Freiburg im Breisgau
P2B001 Study site Englewood,, Englewood
P2B001/003 Study site München, München
P2B001/003 study site Haag, Haag
P2B001/003 Site Scottsdale, Scottsdale
P2B001/003 study site Scottsdale, Scottsdale
P2B001/003 Study site Albuquerque, Albuquerque
P2B001/003 study site Ulm, Ulm
P2B001 site Los Angeles, Los Angeles
P2B001/003 study site Honolulu, Honolulu
P2B001/003 Site Kirkland, Kirkland
P2B001 Study Vernon, Vernon
P2B001/003 study site Boston, Boston
P2B001/003 study site New Hampshire, Lebanon
P2B001/003 Study site Camden, Camden
P2B001 Study site Edison, Edison
P2B001/003 study site Toronto, Toronto
P2B001/003 Study site Haag, Haag
P2B001/003 site Munich, Munich
P2B001/003 Study site Dresden, Dresden
P2B001/003 study site Leipzig, Leipzig
P2B001/003 study site Gera Germany, Gera
P2B001/003 Study site Gera, Gera
P2B001/003 Study site Sant Cugat del Vallés, Sant Cugat Del Vallés
P2B001/003 Study site Barcelona, Barcelona
P2B001/003 Study site Vall d'Hebrón, Barcelona
Lead Sponsor
Pharma Two B Ltd.
INDUSTRY